Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 13Breast 6Head & Neck 5Gastrointestinal 5Gynecologic 3Dermatologic 3Thoracic 2Sarcoma 2Lymphoid 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1CNS 1

Conditions

Ovarian Neoplasms 24Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Fallopian Tube Neoplasms 7Carcinoma, Renal Cell 6Breast Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Colorectal Neoplasms 5Stomach Neoplasms 4Recurrence 4Melanoma 4Carcinoma, Non-Small-Cell Lung 4Vulvar Neoplasms 3Vaginal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Uterine Neoplasms 2Neoplasms 2Lymphoma 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1

Interventions

pembrolizumab 14Specimen Handling 8Docetaxel 8olaparib 7Nivolumab 7Gemcitabine 7Trastuzumab 6Paclitaxel 6rucaparib 5Magnetic Resonance Spectroscopy 5Early Intervention, Educational 5Biopsy 5Standard of Care 4Cyclophosphamide 4Carboplatin 4tisotumab vedotin 3talazoparib 3pertuzumab 3durvalumab 3atezolizumab 3Taxes 3Surveys and Questionnaires 3Sirolimus 3Radiotherapy 3Psychiatric Rehabilitation 3Methods 3Irinotecan 3Immunoglobulin G 3Fulvestrant 3Educational Status 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms × durvalumab × Gynecologic × Clear all
NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

Phase 1 Active not recruiting
120 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Maastricht University Medical Center

Phase 1/2 Recruiting
126 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03518606 2025-01-15

MOVIE

UNICANCER

Phase 1/2 Completed
126 enrolled
BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡